ceo commentari new hire point turnaround potenti
maintain market outperform rate lower price target
follow yesterday releas
result new target base unchang ep
estim vs prior ep
whole first quarter result solid versu guidanc street
expect three largest divis repres
mix post modest upsid versu street deliv beat total sale
despit one less sell day quarter adjust ep came ahead
initi full-year guidanc offer call sale bln
y/i flattish cc bp posit fx impact ep
compar street bln ep head
despit varianc midpoint ep rang stock trade
intra-day indic us investor perceiv bar
set low enough thing improv year progress suppli
gradual restor
new ceo bryan hanson emphas increment confid
compani outlook compar last quarter although potenti risk
linger hanson reiter five prioriti right ship includ
enhanc cultur drive on-going remedi program suppli
recoveri scale new product launch make invest drive
ceo also express excit compani new top talent infus
includ cole lannum svp ir ken tripp svp
rachel ellingson st jude svp strategi
mr hanson bring new addit also restructur manag
better align leadership result cori bruno presid spine pedro malha
head dental angela main chief ethic complianc offic name
report directli ceo
manag focus resolv on-going remedi
obstacl compani announc fda made addit observ
recent inspect warsaw north campu facil
slightli posit note number observ less fda previou
inspect indic progress like made
thomson reuter jmp secur llc
compani report jmp secur llc
report read conjunct import disclosur inform includ attest regul analyst certif
suppli front believ still track substanti restor key brand knee
hip set begin hanson cite three justif reach recoveri
time lack schedul interrupt past quarter de-risk key recoveri
mileston on-board recent high-level leadership
sever new key product launch help drive top-lin result pipelin featur
addit persona knee famili includ cementless revis product limit
launch two item accompani partial knee launch fall full
platform launch expect notabl releas includ limit launch rosa
knee comprehens augment basepl set categori
total sale bln y/i cc versu street bln estim
bln guidanc bln high end total price
continu recent trend volum fx benefit provid respect
adjust ep vs last year consensu estim
america sale bln y/i cc emea revenu mln
y/i cc asia pacif sale mln y/i cc
knee hip came street expect estim knee sale
mln higher consensu y/i cc growth volum
benefit fx partial off-set price total hip sale mln beat
consensu y/i cc posit volum growth fx
price
far divis set post growth cc spine cmf
dental moder declin spine cmf cc dental declin
guid bln expect de-lever primari use
stock remain inexpens versu peer vs peer ep still
think merger yield mani advantag longer term manag believ return
industry-lik mid-singl digit sale growth least equival market rate
double-digit ep growth potenti remain realist may take littl time get
manag provid full-year guidanc usual suppli quarterli basi
anticip revenu bln bp fx ep expect
rang tax free cash flow bln
figur highlight actual vs jmp estim rang revenu metric along select
 edeltacommentsreconstruct cc america cc emea cc apac cc strong growth persona person knee system continu posit recept persona partial launch fall cc america cc emea cc apac cc warsaw campu suppli constraint linger steadili improv posit growth taperloc complet acetabular annual bpstotal larg cc compani believ could posit growth engin invest drive attract subcategori suppli constraint linger productsannu cc realign product portfolio restructur sale organ certain key marketsannu bpsspine cc strong perform mobi-c cervic disc focus resolut salesforc integr dis-synergi fda clearanc rosa brain ccannual bpstotal blnannual bpsgross bpsdown bp y/i due continu increment manufactur inventori cost warsaw campu price declin neg y/i fx bpsup bp bpsoper bpstax bpsnet zimmer biomet hold inc
largest pure-play public musculoskelet compani long histori stand-alone med-tech firm zimmer spun
manag remain commit orthoped root reconstruct implant still garner major total
revenu today focu bless curs larg depend upon fundament underli hip knee
market biomet acquisit complet reinforc zimmer orthoped focu creat much larger presenc key
highli lever recon market focu challeng depend underli fundament volum rebound
core orthoped arena may occur price like remain headwind across sector new product may perform well
anticip signific ou exposur primarili europ asia may subject headwind tailwind aris
geographi new market entrant may introduc novel devic procedur busi model could significantli chang market
dynam time make difficult compet sizabl larg tradit product portfolio
research analyst prepar report does/do herebi certifi view present report accord my/our
person view secur issuer discuss report mandat sec regul ac part my/our compens
directli indirectli relat specif view recommend express herein certif made
oblig set forth sec regul ac person entiti may use purpos certif made base
my/our analysi date report public i/w assum oblig updat certif reflect fact circumst
event may subsequ come my/our attent sign david turkali daniel stauder
